A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy

Trial Profile

A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2013

At a glance

  • Drugs Ulodesine (Primary) ; Allopurinol; Pneumococcal vaccine; Tetanus vaccine
  • Indications Gout; Pneumococcal infections; Tetanus
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2012 Results reporting changes in xanthine and hypoxanthine levels and presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 14 Nov 2012 Extension study results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 09 Jun 2012 Tolerability results presented at the 13th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top